Trials / Recruiting
RecruitingNCT06213038
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
An Open-label, Dose-escalation Study to Evaluate the Safety, Preliminary Efficacy, Immunogenicity and Pharmacokinetic Characteristics of SKG0106 Intraocular Solution After Single Intravitreal Injection in Chinese Patients With Neovascular (Wet) Age-related Macular Degeneration
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Youxin Chen · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical study to evaluate the safety, preliminary efficacy, immunogenicity of SKG0106 in subjects with nAMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | SKG0106 | SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product |
Timeline
- Start date
- 2023-05-05
- Primary completion
- 2025-05-30
- Completion
- 2025-05-30
- First posted
- 2024-01-19
- Last updated
- 2025-01-08
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06213038. Inclusion in this directory is not an endorsement.